Abstract
Cyclophosphamide is a urotoxic agent that increases the incidence of malignant neoplasms of the urinary tract. The aim of this study was to evaluate the long-term impact of cyclophosphamide on patients with a history of superficial bladder cancer. Between July 1986 and January 1988, 58 consecutive patients with primary superficial transitional cell carcinoma of the bladder were included in this study. All patients had a transurethral R0 resection. Then 6 weekly intravesical instillations of 120 mg bacillus Calmette-Guérin (BCG) were performed. Until June 1987, 22 consecutive patients (group A) received an additional intravenous application of 700 mg/m2 cyclophosphamide prior to the BCG immunotherapy, while from July 1987 36 patients were treated without cyclophosphamide. Survival was calculated using the Kaplan-Meier method and comparison of survival using the log rank test. Tumor staging, grading, and size were equally distributed in both groups. No significant difference could be observed regarding the 10-year overall survival rate (group A: 59%, group B: 58%), the 10-year tumor-specific survival rate (89 vs 94%), and the 10-year progression-free survival rate (85 vs 97%). There was a statistically significant deterioration of the 10-year recurrence-free survival rate in the cyclophosphamide group (44 vs 70%, log rank test: p<0.05). Whereas there were no recurrences in the upper urinary tract among the patients of group B, 2 of the 22 patients from group A developed cancer of the renal pelvis. In patients with a history of superficial bladder cancer, a single dose of cyclophosphamide poses a significantly increased risk of tumor recurrence in the lower and in the upper urinary tract as well.
Similar content being viewed by others
References
Morrison AS (1984) Advances in the etiology of urothelial cancer. Urol Clin North Am 11:557–569
O’Keane JC (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide. N Engl J Med 319:871
Adolphs HD, Bastian HP (1986) Chemoimmunprophylaxe beim oberflächlichen Harnblasenkarzinom. Urologe A 2:51–54
Colvin M (1982) The alkylating agents. In: Chabner BA (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 276–308
Sauer H (1996) Substanzprofile: Zytostatika, Hormone, Zytokine. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New York, pp 467–471
Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477–484
Worth PHL (1971) Cyclophosphamide and the bladder. Br Med J 3:182
Pedersen-Bjeergard J, Ersboll J, Hansen VL (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin’s lymphoma. N Engl J Med 318:1028–1032
Pearson RM, Soloway MS (1978) Does cyclophosphamide induce bladder cancer? Urology 11:437–447
Kawamura J, Sakurai M, Tsukamoto K, Tochigi H (1993) Leiomyosarcoma of the bladder eighteen years after cyclophosphamide therapy for retinoblastoma. Urol Int 51:49–53
Carney CN, Stevens PS, Fried FA, Mandell J (1982) Fibroblastic tumor of the urinary bladder after cyclophosphamide therapy. Arch Pathol Lab Med 106:247–249
Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714
Czerny T (1996) Begleittherapie bei Ifosfamid und Cyclophosphamid. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New York, pp 1144–1147
Chodak GW, Straus FW, Schoenberg HW (1981) Simultaneous occurrence of transitional, squamous, and adenocarcinoma of the bladder after 15 years of cyclophosphamide ingestion. J Urol 125:424–426
Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow up study. Arthritis Rheum 38:1120–1127
Tuttle TM, Williams GM, Marshall FF (1988) Evidence for cyclophosphamide-induced transitional cell carcinoma in a renal transplant patient. J Urol 140:1009–1011
Adolphs HD, Bastian HP (1983) Chemoimmune prophylaxis of superficial bladder cancer. J Urol 129:29–32
Soloway MS (1977) Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37:2918–2929
Durkee C, Benson R (1980) Bladder cancer following administration of cyclophosphamide. Urology 16:145–148
Fernandes ET, Manivel JC, Reddy PK, Ercole CK (1996) Cyclophosphamide associated bladder cancer—a highly aggressive disease: analysis of 12 cases. J Urol 156:1931–1933
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Volkmer, B.G., Seidl-Schlick, E.M., Bach, D. et al. Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. Clin Rheumatol 24, 319–323 (2005). https://doi.org/10.1007/s10067-004-1032-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-1032-2